Won trial for pharmaceutical company in high-stakes Hatch-Waxman patent litigation involving client’s best-selling anesthetic drug and obtained a permanent injunction blocking market entry by competitor on all three asserted patents.
Successfully obtained freedom to operate for biopharmaceutical company in high-stakes inventorship litigation over 37 US and international patents concerning peptide therapies that stimulate red blood cell formation.
Won trial court and Federal Circuit victories and obtained a permanent injunction for leading pharmaceutical company in Hatch-Waxman patent case involving billion-dollar anti-ulcer, heartburn, and acid reflux drug.
Successfully assisted biosimilar manufacturer in invalidating key blocking patents, overcoming multiple barriers to entry, navigating the BPCIA, and launching major biosimilar antibody product several years ahead of schedule.
Won multiple summary judgments of noninfringement for leading pharmaceutical company in patent lawsuit targeted at its billion-dollar cancer drug and its international cancer research program.
Successfully represented biopharmaceutical company in asserting its crown-jewel patents relating to humanized antibodies and obtained lucrative licenses from market-leading pharm company for four blockbuster biologic drugs.